Discover more from FarmaKology’s Substack
FarmaKology Newsletter - Issue #83
JanOne is a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. As a result, we hope to reduce the need for prescribing dangerous opioid drugs. Our first drug candidate is a treatment for Peripheral Arterial Disease (PAD), a condition that can cause severe pain and affects over 8.5 million people in the US alone.
Envigo announces collaboration with Biocytogen to distribute the B-NDG triple immunodeficient and humanizable mouse mode
Envigo RMS Holding Corp. announces a collaboration with Biocytogen, a global biotech company that drives the research and development of new drugs with innovative technologies. The two companies are committed to supporting research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the United States, Europe, and certain Asia-Pacific regions.
African Research Foundation Partners With International Pharmaceutical Industry to Strengthen Capacity for Health Innovation in Africa
H3D-Foundation (H3D-F) and the International Federation of Pharmaceutical Manufacturers and Associations announced a three-year partnership to strengthen capacity for health innovation in Africa. The two organizations will combine forces to focus on driving capacity strengthening for drug discovery and development in Africa by scaling existing initiatives and identifying new development opportunities for young and mid-career scientists in the region.
Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the Accelerated Approval Pathway
Eisai Co., Ltd. and Biogen Inc. announced that Eisai has initiated a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab (BAN2401), the company’s investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s disease (early AD). The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial (Study 201) in people with early AD and confirmed amyloid pathology.
Boehringer Ingelheim and Invetx announce strategic collaboration to advance monoclonal antibody biotherapeutics in animal health
Boehringer Ingelheim, a global leader in animal health, and Invetx, a Boston-based pioneer in protein-based therapeutics for animal health, announce that they have entered into a collaboration agreement to develop novel, species-specific monoclonal antibody biotherapeutics targeting a wide range of diseases in the veterinary species, initially focused on dogs and cats.